Specifically targeted antiviral therapy for hepatitis C virus.
Specifically targeted antiviral therapy for hepatitis C virus.
复制标题
针对丙型肝炎病毒的专门靶向抗病毒治疗。
DOI：
--
复制
发表时间：
2007
影响因子：
4.3
通讯作者：
R. Flisiak
中科院分区：
文献类型：
--
作者：
A. Parfieniuk;J. Jaroszewicz;R. Flisiak
丙型肝炎病毒（HCV）感染影响全世界1.8亿人，主要流行是基因型1感染，其次是基因型2和3。标准抗HCV治疗目前旨在增强对病毒的自然免疫应答，而新的治疗概念直接靶向HCV RNA和病毒酶或影响宿主-病毒相互作用。目前正在开发的新型治疗方案主要集中在HCV特异性酶、NS 3蛋白酶和NS 5 B聚合酶的抑制剂上。这些药物协同作用代表了HCV特异性靶向抗病毒治疗（STAT-C）的概念。STAT-C是一种有吸引力的策略，其主要目标是增加所有基因型的抗病毒反应的有效性，具有更短的治疗持续时间和更好的耐受性。然而，耐药突变的出现限制了这些化合物在单药治疗中的使用，使治疗方案复杂化。因此，未来HCV治疗的可预测方案将是具有不同作用机制的药物组合。目前看来，干扰素在不久的将来仍将是任何新的抗HCV治疗方案的基本组成部分;因此，开发比聚乙二醇干扰素更有效、毒性更低、更方便的干扰素形式是一种压力。
Hepatitis C virus (HCV) infection affects 180 million people worldwide with the predominant prevalence being infection with genotype 1, followed by genotypes 2 and 3. Standard anti-HCV therapy currently aims to enhance natural immune responses to the virus, whereas new therapeutic concepts directly target HCV RNA and viral enzymes or influence host-virus interactions. Novel treatment options now in development are focused on inhibitors of HCV-specific enzymes, NS3 protease and NS5B polymerase. These agents acting in concert represent the concept of specifically targeted antiviral therapy for HCV (STAT-C). STAT-C is an attractive strategy in which the main goal is to increase the effectiveness of antiviral responses across all genotypes, with shorter treatment duration and better tolerability. However, the emergence of resistant mutations that limit the use of these compounds in monotherapy complicates the regimens. Thus, a predictable scenario for HCV treatment in the future will be combinations of drugs with distinct mechanisms of action. For now, it seems that interferon will remain a fundamental component of any new anti-HCV therapeutic regimens in the near future; therefore, there is pressure to develop forms of interferon that are more effective, less toxic, and more convenient than pegylated interferon.